Publications by authors named "A Smolin"
Background: Prolgolimab is an IgG1 anti-PD-1 monoclonal antibody with the Fc-silencing 'LALA' mutation. The phase III DOMAJOR study assessed efficacy and safety of prolgolimab in combination with pemetrexed and platinum-based chemotherapy vs placebo in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Methods: 292 patients with advanced non-squamous NSCLC were randomized 1:1 to receive 4 cycles of pemetrexed, platinum-based drug and either prolgolimab (3 mg/kg Q3W) or placebo followed by prolgolimab/placebo with pemetrexed until disease progression or toxicity (≤36 months).
The most time-consuming aspect of dental prosthesis installation is the osseointegration of a metal implant with bone tissue. The acceleration of this process may be achieved through the use of extracorporeal shock wave therapy. The objective of this study is to investigate the conditions for osseointegration of the second premolar implant in the mandibular segment through the use of a poroelastic model implemented in the movable cellular automaton method.
View Article and Find Full Text PDFArticle Synopsis
- Simlukafusp alfa (FAP-IL2v) is an engineered immune cytokine aimed at enhancing immune responses specifically in tumor environments, and was evaluated with atezolizumab for treating recurrent/metastatic cervical squamous cell carcinoma (SCC) in a phase 2 study.
- A total of 48 patients with advanced cervical SCC who had previously received treatment were enrolled; the study primarily measured the objective response rate, yielding a 27% response with a median duration of 13.3 months for those who responded.
- The combination treatment showed clinical efficacy with manageable side effects, including immune cell activation, indicating a promising approach for this patient group.
Effect of patient-specific factors on regeneration in lumbar spine at healthy disc and total disc replacement. Computer simulation.
Comput Methods Programs Biomed
June 2024
Background And Objective: Degenerative diseases of the spine have a negative impact on the quality of life of patients. This study presents the results of numerical modelling of the mechanical behaviour of the lumbar spine with patient-specific conditions at physiological loads. This paper aims to numerically study the influence of degenerative changes in the spine and the presence of an endoprosthesis on the creation of conditions for tissue regeneration.
View Article and Find Full Text PDFObjectives: In the Phase I/III IMpower133 study, first-line atezolizumab plus carboplatin and etoposide (CP/ET) treatment for extensive-stage small cell lung cancer (ES-SCLC) significantly improved overall survival (OS) and progression-free survival versus placebo plus CP/ET. We explored patient and disease characteristics associated with long-term survival in IMpower133, and associations of differential gene expression and SCLC-A (ASCL1-driven), SCLC-N (NEUROD1-driven), SCLC-P (POU2F3-driven), and SCLC-inflamed (SCLC-I) transcriptional subtypes with long-term survival.
Materials And Methods: Patients with previously untreated ES-SCLC were randomized 1:1 to four 21-day cycles of CP/ET with atezolizumab or placebo.